Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
April 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 |
May 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
Press releases published on March 2, 2025
AION Healthspan Launches First-in-Human Clinical Trial for REJUVXL™ Cell Therapy in Chronic Kidney Disease
EIN Presswire
·
March 2, 2025
AION Healthspan announces enrollment for its first-in-human Phase I/II clinical trial in Diabetic Nephropathy and other forms of Chronic Kidney Disease. MIAMI, FL, UNITED STATES, March 2, 2025 /EINPresswire.com/ -- AION Healthspan, Inc., a clinical- …
Healthcare Waste Treatment Market to Reach $31.4 Billion, Globally, by 2035 at 5.5% CAGR: Allied Market Research
GlobeNewswire
·
March 2, 2025
Wilmington, Delaware, March 02, 2025 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Healthcare Waste Treatment Market by Treatment (Incineration, Autoclaving, Chemical Treatment, and Others), Type of Waste (Hazardous waste and Non- …
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain
GlobeNewswire
·
March 2, 2025
THE WOODLANDS, Texas, March 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will hold a conference call and webcast on Monday, March 3, 2025 at 8:00 a.m. ET to share topline results from the Phase 2b …
Merus gibt Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 bekannt und berichtet über die Geschäftsentwicklung
GlobeNewswire
·
March 2, 2025
- Phase-III-Zulassungsstudien zu Petosemtamab in Kombination mit Pembrolizumab in der Erstlinienbehandlung des PD-L1-positiven rezidivierten/metastasierten Kopf-Hals-Plattenepithelkarzinoms (r/m HNSCC) und Petosemtamab als Monotherapie in der Zweit-/ …
Merus annonce les résultats financiers de son quatrième trimestre et de l’ensemble de son exercice 2024, et fait le point sur ses activités
GlobeNewswire
·
March 2, 2025
- Inclusion en cours pour les études d’enregistrement de phase III visant l’évaluation du pétosemtamab en association avec le pembrolizumab en traitement de 1ᵉ ligne pour un CETC r/m PD-L1 et l’évaluation du pétosemtamab en monothérapie de 2ᵉ et 3ᵉ ligne …